The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax
Serdiuk AV, Levitskiĭ GN, Miasoedov NF, et al. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2007;107:29-39.
What it found
Semax did not change nerve damage measured by electromyography or functional ALS scores. Total quality-of-life scores improved, mainly in emotional state and motivation, with the largest effect on day 10.
Limitations
Article in Russian. Open-label, no control group, 27 patients, short follow-up.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.